Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFsBenzinga • 09/18/25
No more need for needles: A new generation of GLP-1 weight-loss drugs in pill form is coming closerWSJ • 09/18/25
Novo Nordisk's Wegovy Outperforms Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke, And Death: StudyBenzinga • 09/18/25
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 30, 2025 in Novo Lawsuit - NVOPRNewsWire • 09/18/25
Novo Nordisk Stock Jumps. New Ozempic Data for Seniors Beats Rival Eli Lilly Medicine.Barrons • 09/18/25
Novo Nordisk A/S: Ozempic® reduces the risk of heart attack, stroke and death by 23% compared to dulaglutide in the first head-to-head real-world studyGlobeNewsWire • 09/18/25
Wegovy pill offers 'significant' weight reduction, Novo Nordisk says, as oral obesity drug race intensifiesCNBC • 09/18/25
Novo Nordisk's oral semaglutide 25 mg (Wegovy® in a pill*) delivered 16.6% weight loss in people with obesity in a newly published studyGlobeNewsWire • 09/17/25
NVO DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important September 30 Deadline in Securities Class Action - NVOGlobeNewsWire • 09/17/25
NVO Stock Rises on Upbeat Phase III Data for Cagrilintide in ObesityZacks Investment Research • 09/17/25
Eli Lilly's obesity pill outperforms Novo Nordisk's oral drug in head-to-head diabetes trialCNBC • 09/17/25
NOVO NORDISK A/S (NYSE: NVO) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action by September 30, 2025PRNewsWire • 09/17/25